The company has acquired seven established medicine
brands from Iceland drug major Actavis to kick start its polish operations.
The deal has been carried out through Glenmark's Czech subsidiary
Medicamenta which acquired seven brands from Actavis and Biovena (an
affiliate of Actavis in Poland) for an undisclosed sum.
Glenn Saldanha, managing director and CEO, Glenmark said that the portfolio
acquisition will "accelerate growth in a very promising central and east
european market".